The Pharma Data

JANUARY 20, 2021

based Gritstone Oncology is developing a novel COVID-19 vaccine based on adenovirus and messenger-RNA technology designed to combat future variants of the coronavirus. Emeryville, Calif.-based

Vaccine 52

Vaccine RNA Trials Research 52

The Pharma Data

JULY 6, 2021

Sanofi highlights scientific innovations in the field of rare blood disorders at I STH 2021. Editor’s Note: About fitusiran: Fitusiran is an investigational, subcutaneously administered, small interference RNA therapeutic in development for the prophylaxis treatment of people with hemophilia A or B, with or without inhibitors.

Therapies 52

Therapies Pharmacokinetics Treatment RNA 52

The Pharma Data

FEBRUARY 8, 2021

Fitusiran is an investigational, subcutaneously administered small interference RNA therapy in development for the treatment of people with hemophilia A or B, with or without inhibitors.

RNA 52

RNA Treatment Vaccine Therapies 52

Broad Institute

OCTOBER 16, 2024

William Studier receives the 2024 Merkin Prize in ceremony at the Broad Institute for developing technology used to produce millions of doses of COVID-19 vaccines The groundbreaking, scalable technology is widely used in laboratories around the world today to efficiently produce large amounts of protein and RNA. Merkin (left) and F.

Vaccine 64

Vaccine RNA Laboratories Molecular Biology 64

The Pharma Data

JULY 12, 2021

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from the company’s HIV clinical development program at the 11th International AIDS Society Conference on HIV Science (IAS 2021) from July 18-21. Late Breaking Oral Presentation OALC01LB03. Indications and Usage for DELSTRIGO.

Pharmacokinetics 52

Pharmacokinetics Clinical Trials Trials Treatment 52

PLOS: DNA Science

MAY 16, 2024

from April 15, 2021: “A leap from the RaTG13 virus found in the bat muck of the abandoned mine in 2013 to the emergence of SARS-CoV-2 in 2019 is like reading the first and last chapters of a novel: there’s not enough of a plot to reconstruct a story. Work on vaccines ensued too. • Single-cell sequencing.

Virus 98

Virus DNA RNA Science 98

The Pharma Data

APRIL 30, 2021

April 30, 2021 /PRNewswire/ — AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2021. “We are off to an excellent start to 2021, with strong performance across our core therapeutic areas and first quarter revenue and earnings results ahead of our expectations,” said Richard A. .

FDA 40

FDA Production Treatment International 40

The Pharma Data

JANUARY 14, 2021

14, 2021 — Multifocal microvascular injury has been observed in the brain and olfactory bulbs in postmortem observation of patients who died from COVID-19 , according to a research letter published online Dec. © 2021 HealthDay. . © 2021 HealthDay. Posted: January 2021. Professional. THURSDAY, Jan.

RNA 52

RNA Virus Research 52

The Pharma Data

AUGUST 16, 2021

The antiviral agent incorporates RNA-like building blocks into the RNA genome of the virus. If this genetic material is further replicated, defective RNA copies are produced and the pathogen can no longer spread. When it enters the cell, it is converted into RNA-like building blocks. 2021 Aug 11.

RNA 52

RNA Virus Clinical Trials Drugs 52

The Pharma Data

JANUARY 10, 2021

11, 2021 07:11 UTC. The VIR Seek SARS-CoV-2 Solution is a comprehensive workflow for the detection of SARS-CoV-2 on environmental surfaces that includes swabbing of environmental surfaces, RNA extraction, analysis by Reverse Transcription PCR (RT-PCR) and evaluation by an advanced algorithm.

RNA 52

RNA Virus Research 52

KIF1A

MAY 4, 2024

This has been a long and fruitful collaboration, with KIF1A.ORG hosting students in 2021 and 2022; one alumni includes our very own board member Michelle Tao! Later, she developed an interest in the RNA world, specifically focusing on alternative splicing and its correlation with neuron cell properties within and across cell types.

Science 116

Science Medical Schools Research RNA 116

Codon

DECEMBER 12, 2024

DNA and RNA molecules are also built from exclusively right-handed nucleic acids. Across the tree of life, organisms strictly require exactly one of the two chiral forms of their molecular building blocks — amino acids, nucleotides of RNA and DNA. 4 As far as we know, right-handed proteins never occur naturally.

RNA 104

RNA DNA Vaccine Virus 104

Drug Target Review

AUGUST 9, 2023

14 TDP-43 is a DNA and RNA binding protein that regulates the expression and splicing of several target transcripts. Many potential toxic effects have been suggested, including the mis-splicing of the Stathmin-2 RNA transcript. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis.” 154, July 2021, p.

RNA 98

RNA Regulations Disease DNA 98

The Pharma Data

JANUARY 22, 2021

22, 2021 — The U.S. Before initiating Cabenuva treatment, study participants were virologically suppressed (HIV-1 RNA <50 copies/mL). © 2021 HealthDay. Posted: January 2021. FRIDAY, Jan. Approval of Cabenuva and Vocabria was granted to ViiV Healthcare. More Information. All rights reserved. Source link.

FDA Approval 52

FDA Approval FDA RNA Clinical Trials 52

PLOS: DNA Science

JUNE 13, 2024

The most compelling evidence for the origin lies in the RNA genome sequence similarities between RaTG13 and SARS-CoV-2 – specifically, a part that encodes the “furin binding site” of the spike protein with which the virus adheres to host cells. ” So ended my 2021 blog post a month later.

Virus 52

Virus RNA DNA Science 52

Broad Institute

MAY 2, 2024

Today, she is a senior associate computational biologist in the Getz lab, where she applies computational techniques to DNA and RNA sequencing data to analyze rapid autopsy samples, taken from multiple sites throughout the body at the time of a cancer patient’s death. Tell us a bit about your research.

Science 124

Science Medical Schools Disease Hospitals 124

The Pharma Data

OCTOBER 27, 2020

European market launch of both COVID-19 tests planned for Q1 2021. The test is planned for commercial launch as a CE-IVD ( in vitro diagnostic) certified product in the European Union in Q1 2021. “We are currently developing two saliva-based tests to detect SARS-CoV-2 RNA.

RNA 52

RNA Production International Compliance 52

Drug Target Review

AUGUST 24, 2023

Her discoveries on the first-in-class RNA-based innate immune receptor agonist RGT100, built the foundation for the initiation of a Phase I clinical trial as well as the successful acquisition of Rigontec by MSD (known as Merck & Co. 2021 Jul 6;120(13):2644-56. 2021 Dec 1;9(12):1425-38. 2021 Jun 17;12:685370.

Treatment 98

Treatment Therapies Clinical Development Cell Biology 98

The Pharma Data

MARCH 8, 2021

These preliminary findings were presented today during Science Spotlights TM at the 2021 Conference on Retroviruses and Opportunistic Infections (CROI 2021). Findings from the primary efficacy and safety endpoints and additional secondary objectives will be presented at an upcoming medical meeting. About Molnupiravir.

Trials 69

Trials Virus RNA Research Laboratories 69

The Pharma Data

NOVEMBER 17, 2021

Mount Sinai researchers have developed a new model that uses DNA and RNA sequencing data from hundreds of patients to identify specific genes and genetic alterations responsible for never-before-defined subtypes of a blood cancer called multiple myeloma. doi: 10.1126/sciadv.abg9551. Source link: [link].

Treatment 52

Treatment RNA DNA Science 52

The Pharma Data

OCTOBER 21, 2020

AT-527 is expected to be ideally suited to combat COVID-19 as it inhibits viral replication by interfering with viral RNA polymerase, a key component in the replication machinery of RNA viruses. Importantly, the manufacturing process for our small molecule direct-acting antiviral allows us to produce AT-527 quickly and at scale.”.

RNA 52

RNA Pharmaceuticals Virus Clinical Trials 52

The Pharma Data

MAY 4, 2021

Posted 04 May 2021 | By Kari Oakes . CureVac’s CVnCoV COVID-19 vaccine and NVX-CoV2372, the Novavax candidate, have been under review since February 2021. © 2021 Regulatory Affairs Professionals Society. In this way, the rolling review speeds the path to a regulatory decision. . EMA. . . . . . Source link.

Vaccine 52

Vaccine RNA Clinical Trials Marketing 52

The Pharma Data

MAY 17, 2021

Sanofi has also entered into vaccine manufacturing partnerships to help produce the Pfizer/BioNTech, Moderna and Johnson & Johnson shots ( DID , April 13 ), and it is developing a messenger RNA-based vaccine candidate with Translate Bio. The mRNA candidate is currently being assessed in a phase 1/2 study.

Vaccine 40

Vaccine Immune Response RNA Virus 40

Codon

JUNE 25, 2024

Proteins are colored blue and RNA molecules are colored orange and yellow. For a 2021 paper, researchers at the California Institute of Technology estimated how long it would take E. RNA and proteins comprise each ribosome, but the cell synthesizes these two biomolecules at different rates. Nature Microbiology (2021).

DNA 82

DNA RNA Laboratories Research 82

Broad Institute

MARCH 5, 2024

In this talk, we are motivated by unsupervised problems that arise in the analysis of single cell RNA sequencing data, where sample splitting does not allow us to avoid double dipping. Unfortunately, in some problems, sample splitting is unattractive or impossible.

RNA 40

RNA 40

Vial

DECEMBER 5, 2023

Transforming Genomics Research Next-generation sequencing (NGS) enables comprehensive genome sequencing and has transformed genomics research, offering vastly improved capabilities for analyzing DNA and RNA in a high-throughput and cost-effective manner. Zeng et al. A study by Park et al.

Clinical Trials 52

Clinical Trials Trials RNA Bioinformatics 52

The Pharma Data

JANUARY 21, 2021

21, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. In the ATLAS study, CABENUVA met the primary endpoint for noninferiority (the proportion of participants with plasma HIV-1 RNA ?50 Two percent of patients in both treatment arms had an HIV-1 RNA count ?50

FDA Approval 52

FDA Approval Treatment RNA FDA 52

The Pharma Data

JANUARY 31, 2021

Clover plans to initiate a global phase 2/3 trial in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

MAY 3, 2021

Posted 03 May 2021 | By Kari Oakes . Pfizer reported that it submitted its application for extension of authorization last week, and EMA announced today that it has undertaken the evaluation of the messenger RNA (mRNA) vaccine. © 2021 Regulatory Affairs Professionals Society. EMA. . . . Source link.

Vaccine 52

Vaccine RNA Clinical Trials Packaging 52

The Pharma Data

MARCH 8, 2021

Week 96 findings reinforce the primary (proportion of participants with plasma HIV-1 RNA ?50 50 c/mL at Week 48 (Snapshot, ITT-E)), and secondary endpoints (proportion of participants with plasma HIV-1 RNA ?50 These data were presented at the virtual Conference on Retroviruses and Opportunistic Infections (CROI 2021).

RNA 52

RNA Treatment Therapies Licensing 52

The Pharma Data

MAY 17, 2021

Pending positive outcomes of that trial and regulatory reviews, the companies anticipate their vaccine being given emergency use approval in the fourth quarter of 2021. Beginning in February 2021, the trial enrolled 722 volunteers in the US and Honduras. First results are expected in the third quarter of 2021. Phase 2 study ?.

Immune Response 52

Immune Response Vaccine Trials RNA 52

The Pharma Data

AUGUST 16, 2021

The CureVac-GSK COVID-19 collaboration announced in February 2021 extends the existing strategic mRNA technology partnership both companies started in July 2020, which focuses on the development of new products based on CureVac’s second-generation RNA-technology for different targets in the field of infectious diseases.

Immune Response 52

Immune Response Vaccine Virus RNA 52

The Pharma Data

JANUARY 31, 2021

Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax’s CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. EMERYVILLE, Calif. and CHENGDU, China , Feb.

Vaccine 52

Vaccine Trials Virus RNA 52

Drug Target Review

SEPTEMBER 25, 2024

2021 Oct 11 [cited 2024 Sep 4];13(20):5081. 2021 Apr [cited 2024 Sep 4];2(4):377–91. Preclinical studies in models of EGFR-mutated NSCLC, KRAS G12C-mutated NSCLC and colorectal cancer (CRC) demonstrated that TT125-802 prevents the development of resistance to EGFR inhibitors and KRAS G12C inhibitors, respectively. Cancers [Internet].

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

Broad Institute

OCTOBER 11, 2023

By early 2021, Calico and AbbVie had launched two early-stage clinical trials testing two PTPN2 inhibitors, either as a single therapy or in combination with existing PD-1 immunotherapies. The team found that deleting the gene Ptpn2 made tumors sensitive to PD-1 therapy, and they published their findings in Nature in 2017.

Research 137

Research Immune Response Clinical Trials Therapies 137

The Pharma Data

NOVEMBER 7, 2020

Flow cytometry and RNA sequencing analysis demonstrated these cells to be both cytotoxic and actively proliferating. Furthermore, RNA sequencing suggested that these cells may respond to the immune-related protein interferon, but more research is needed to confirm the significance. 1 in orthopedics (for the 11th consecutive year), No.

Nurses 52

Nurses Hospitals RNA Laboratories 52

The Pharma Data

DECEMBER 8, 2020

BioAge is on the cusp of taking pilot therapies BGE-117 and BGE-175 into clinical trials, targeting the first half of 2021. Laying down a new track for RNA processing, Remix launched with $81 million in financing. co-founder, president and CSO of Remix Therapeutics and Atlas Venture Entrepreneur in Residence. . Pear Therapeutics.

RNA 52

RNA Therapies Disease Protein Expression 52